ATP-IL12

ATP-IL12 is an engineered cytokine drug designed to deliver interleukin-12 (IL-12) activity selectively within the tumor microenvironment. The molecule remains inactive in circulation, thereby reducing the systemic toxicity typically associated with recombinant IL-12 therapy. Upon binding to extracellular ATP, which is abundant in tumors, ATP-IL12 undergoes a conformational change that exposes its active IL-12 component to the IL-12 receptor (IL-12R). This targeted activation aims to stimulate anti-tumor immune responses by promoting Th1 differentiation and IFNγ production while minimizing off-target effects. The drug is being developed primarily for cancer immunotherapy by Bonum Therapeutics[1][2].